HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX)

Analysts at HC Wainwright assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 286.10% from the stock’s previous close. HC Wainwright also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.19) EPS.

Other research analysts also recently issued research reports about the stock. Oppenheimer dropped their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.56.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.59 on Thursday. Perspective Therapeutics has a one year low of $2.32 and a one year high of $19.05. The company’s 50-day moving average is $3.14 and its 200 day moving average is $7.32.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth $33,000. Intech Investment Management LLC purchased a new stake in shares of Perspective Therapeutics in the third quarter worth $137,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth $34,000. Finally, National Bank of Canada FI increased its stake in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.